Carl Icahn disclosed in a regulatory filing no position in Bausch Health (BHC). Icahn has sold his firm’s entire position in Bausch Health.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BHC:
- Durect, Bausch Health merger expected to close in Q3
- Bausch + Lomb price target raised to $13 from $11 at BofA
- Bausch Health reports Q2 GAAP EPS 40c vs. 3c last year
- Bausch Health to acquire Durect for $1.75 per share in cash upfront
- Bausch Health to acquire Durect for $1.75 per share in an all-cash transaction